ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. (ARYX) Revenue
Annual & quarterly revenue history · segment & region breakdown
ARYX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsARYx Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2009.
Revenue trend
2009 – 2003 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2009-12-31 | $0.00B | -$0.02B | -100.00% |
| 2008-12-31 | $0.02B | +$0.02B | +374.36% |
| 2007-12-31 | $0.00B | -$0.00B | -12.26% |
| 2006-12-31 | $0.00B | +$0.00B | — |
| 2005-12-31 | $0.00B | +$0.00B | — |
| 2004-12-31 | $0.00B | +$0.00B | — |
| 2003-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ARYx Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ARYx Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ARYx Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ARYX revenue · 4 questionsARYX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2009.
▸ Source: FMP · ARYx Therapeutics, Inc. SEC filings · GAAP · ARYx Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026